Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (11-20 of 288) with videos related to

Pageof 29
Sort By:
Journal of Thoracic Disease|April 19, 2019
Hyperprogressive disease: a distinct effect of immunotherapy?Vinita Popat, David E Gerber
Current Oncology Reports|March 15, 2023
AXL Inhibitors: Status of Clinical DevelopmentSheena Bhalla, David E Gerber
Seminars in Cancer Biology|September 18, 2016
ALK alterations and inhibition in lung cancerTri Le, David E Gerber
Translational Lung Cancer Research|August 2, 2019
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practiceSawsan Rashdan, David E Gerber
Cancer Journal (Sudbury, Mass.)|May 28, 2013
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapiesPuneeth Iyengar, David E Gerber
Annals of Translational Medicine|February 3, 2017
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapiesSawsan Rashdan, David E Gerber
Expert Opinion on Investigational Drugs|March 21, 2007
Emerging monoclonal antibody therapies for malignant gliomasDavid E Gerber, John Laterra
Cancer Metastasis Reviews|February 9, 2010
Cetuximab in combination therapy: from bench to clinicDavid E Gerber, Hak Choy
Cancers|March 17, 2019
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?Tri Le, David E Gerber
Seminars in Cancer Biology|July 23, 2019
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A reviewShaheen Khan, David E Gerber
Pageof 29

Showing results (11-20 of 288) with videos related to

Sort By:
Pageof 29
Journal of Thoracic Disease|April 19, 2019
Hyperprogressive disease: a distinct effect of immunotherapy?Vinita Popat, David E Gerber
Current Oncology Reports|March 15, 2023
AXL Inhibitors: Status of Clinical DevelopmentSheena Bhalla, David E Gerber
Seminars in Cancer Biology|September 18, 2016
ALK alterations and inhibition in lung cancerTri Le, David E Gerber
Translational Lung Cancer Research|August 2, 2019
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practiceSawsan Rashdan, David E Gerber
Cancer Journal (Sudbury, Mass.)|May 28, 2013
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapiesPuneeth Iyengar, David E Gerber
Annals of Translational Medicine|February 3, 2017
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapiesSawsan Rashdan, David E Gerber
Expert Opinion on Investigational Drugs|March 21, 2007
Emerging monoclonal antibody therapies for malignant gliomasDavid E Gerber, John Laterra
Cancer Metastasis Reviews|February 9, 2010
Cetuximab in combination therapy: from bench to clinicDavid E Gerber, Hak Choy
Cancers|March 17, 2019
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?Tri Le, David E Gerber
Seminars in Cancer Biology|July 23, 2019
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A reviewShaheen Khan, David E Gerber
Pageof 29